vimarsana.com

Latest Breaking News On - எஃப் ஸ்டீபன் ஹோடி - Page 1 : vimarsana.com

Survival benefits of immunotherapy combination persist for more than six years in patients with advanced melanoma

Benefits of immunotherapy combination persist for more than six years in advanced melanoma

 E-Mail Higher percentage of patients treated with nivolumab and ipilimumab in clinical trial reach the six-and-a-half-year survival mark than those treated with either drug alone. BOSTON - In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. The results, stemming from the CheckMate 067 clinical trial, represent a new landmark in survival rates for patients with melanoma treated with immune checkpoint inhibitor drugs. F. Stephen Hodi, MD, the director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Cancer Institute is co-senior author of the study. Findings will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8.

Dana-Farber researchers present key studies at ASCO annual meeting 20 May

Dana-Farber researchers present key studies at ASCO annual meeting 20 May
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.